Brief: Calithera Biosciences Expects To Delay Enrollment Of First Patient In Randomized Keapsake Trial Until Q3

Calithera Biosciences

14/04/2020 12:32

April 14 (Reuters) - Calithera Biosciences Inc  CALA.O :
    * CALITHERA BIOSCIENCES PROVIDES UPDATE ON BUSINESS
OPERATIONS
    * CALITHERA BIOSCIENCES INC - ON TRACK TO ANNOUNCE TOP-LINE
CANTATA RESULTS THIS YEAR, CO IS NARROWING TIMEFRAME TO Q4 OF
2020
    * CALITHERA BIOSCIENCES INC - EXPECTS TO DELAY ENROLLMENT OF
FIRST
PATIENT IN RANDOMIZED KEAPSAKE TRIAL UNTIL Q3 OF 2020
    * CALITHERA BIOSCIENCES INC - PLANS TO PRESENT INTERIM DATA
FROM
RANDOMIZED KEAPSAKE TRIAL IN 2021
    * CALITHERA BIOSCIENCES INC - EXPECTS ENROLLMENT IN PFIZER
CLINICAL COLLABORATION WITH CDK4/6 INHIBITOR IBRANCE TO RESUME
IN Q3 OF 2020
    * CALITHERA BIOSCIENCES INC - EXPECTS TO DELAY ENROLLMENT IN
FIRST
PATIENT FOR CB-280 ARGINASE INHIBITOR PROGRAM UNTIL Q3 OF 2020

Source text for Eikon:  ID:nGNXcfDFyW 
Further company coverage:  CALA.O 

 ((Reuters.Briefs@thomsonreuters.com;))